Skip to main content

Advertisement

SpringerLink
Log in

Tocilizumab for the treatment of TAFRO syndrome: a systematic literature review

  • Review Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

TAFRO syndrome is a newly recognized disease entity characterized by thrombocytopenia, anasarca, fever, reticulin myelofibrosis, renal dysfunction, and organomegaly. The objective of this study was to investigate the effectiveness of tocilizumab, an anti-interleukin-6 receptor antibody, in patients with TAFRO syndrome. We performed a systematic literature review from inception to July 5, 2020, for articles reporting tocilizumab administration for the treatment of TAFRO syndrome. We identified 31 patients with TAFRO syndrome treated with tocilizumab. The mean age was 49.8 years, and 61.3% of the patients were male. The mean observation period was 12.6 months. Tocilizumab was used at the standard intravenous dose (8 mg/kg) weekly or every 2 weeks in combination with other immunosuppressive drugs, such as glucocorticoids, rituximab, cyclosporine, or cyclophosphamide, in most of the patients. Eighteen patients (58.1%) received tocilizumab as a first-line treatment, while it was a second-line or a third-line treatment for 13 patients with insufficient responses to the prior treatments. Sixteen patients (51.6%) obtained complete response to tocilizumab treatment, whereas 15 patients showed only partial or no response. Detailed factors of ineffectiveness included persistent thrombocytopenia (n = 7), persistent anasarca (n = 5), persistent renal dysfunction (n = 2), and persistent fever (n = 2). A total of four patients (12.9%) succumbed to the disease, while the remaining twenty-seven patients survived. Two patients achieved drug-free remission at last visit, and disease remission was maintained with tocilizumab monotherapy in five patients. No new safety signal was reported. Tocilizumab was effective in ~ 50% of the patients, suggesting it could serve as a treatment choice for TAFRO syndrome. Poor clinical response to tocilizumab observed in other patients highlights the need for the additional therapeutic treatment options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data availability

All data in this study are presented in the manuscript.

References

  1. Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, Simpson D, Liu AY, Menke D, Chandrakasan S, Lechowicz MJ, Wong RSM, Pierson S, Paessler M, Rossi JF, Ide M, Ruth J, Croglio M, Suarez A, Krymskaya V, Chadburn A, Colleoni G, Nasta S, Jayanthan R, Nabel CS, Casper C, Dispenzieri A, Fosså A, Kelleher D, Kurzrock R, Voorhees P, Dogan A, Yoshizaki K, van Rhee F, Oksenhendler E, Jaffe ES, Elenitoba-Johnson KSJ, Lim MS (2017) International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 129:1646–1657

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Takai K, Nikkuni K, Momoi A, Nagai K, Igarashi N, Saeki T (2013) Thrombocytopenia with reticulin fibrosis accompanied by fever, anasarca and hepatosplenomegaly: a clinical report of five cases. J Clin Exp Hematop. 53:63–68

    PubMed  Google Scholar 

  3. Kawabata H, Takai K, Kojima M, Nakamura N, Aoki S, Nakamura S, Kinoshita T, Masaki Y (2013) Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop 53:57–61

    PubMed  Google Scholar 

  4. Srkalovic G, Marijanovic I, Srkalovic MB, Fajgenbaum DC (2017) TAFRO syndrome: new subtype of idiopathic multicentric Castleman disease. Bosn J Basic Med Sci 17:81–84

    PubMed  PubMed Central  Google Scholar 

  5. Carbone A, Pantanowitz L (2016) TAFRO syndrome: an atypical variant of KSHV-negative multicentric Castleman disease. Am J Hematol 91:171–172

    PubMed  Google Scholar 

  6. Iwaki N, Fajgenbaum DC, Nabel CS, Gion Y, Kondo E, Kawano M, Masunari T, Yoshida I, Moro H, Nikkuni K, Takai K, Matsue K, Kurosawa M, Hagihara M, Saito A, Okamoto M, Yokota K, Hiraiwa S, Nakamura N, Nakao S, Yoshino T, Sato Y (2016) Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 91:220–226

    CAS  PubMed  Google Scholar 

  7. Masaki Y, Kawabata H, Fujimoto S, Kawano M, Iwaki N, Kotani T, Nakashima A, Kurose N, Takai K, Suzuki R, Aoki S (2019) Epidemiological analysis of multicentric and unicentric Castleman disease and TAFRO syndrome in Japan. J Clin Exp Hematop. 59:175–178

    PubMed  PubMed Central  Google Scholar 

  8. Fujimoto S, Sakai T, Kawabata H, Kurose N, Yamada S, Takai K, Aoki S, Kuroda J, Ide M, Setoguchi K, Tsukamoto N, Iwao-Kawanami H, Kawanami T, Mizuta S, Fukushima T, Masaki Y (2019) Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am J Hematol 94:975–983

    CAS  PubMed  Google Scholar 

  9. Kaneko Y, Atsumi T, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, Miyata M, Murakawa Y, Yasuoka H, Hirata S, Nagasawa H, Tanaka E, Miyasaka N, Yamanaka H, Yamamoto K, Takeuchi T (2016) Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). Ann Rheum Dis 75:1917–1923

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Kaneko Y, Kato M, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, Miyata M, Murakawa Y, Yasuoka H, Hirata S, Tanaka E, Miyasaka N, Yamanaka H, Yamamoto K, Takeuchi T, SURPRISE study group (2018) Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study). Ann Rheum Dis 77:1268–1275

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Akiyama M, Kaneko Y, Kondo H, Takeuchi T (2016) Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis. Clin Rheumatol 35:2829–2834

    PubMed  Google Scholar 

  12. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T (2008) Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 371:998–1006

    CAS  PubMed  Google Scholar 

  13. Kaneko Y, Kameda H, Ikeda K, Ishii T, Murakami K, Takamatsu H, Tanaka Y, Abe T, Takeuchi T (2018) Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis 77:1720–1729

    CAS  PubMed  Google Scholar 

  14. Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schett G, Schulze-Koops H, Spiera R, Unizony SH, Collinson N (2017) Trial of tocilizumab in giant-cell arteritis. N Engl J Med 377:317–328

    CAS  PubMed  Google Scholar 

  15. Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, Nomura A, Yoshida S, Nishimoto N (2018) Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis 77:348–354

    CAS  PubMed  Google Scholar 

  16. Akiyama M, Kaneko Y, Takeuchi T (2020) Tocilizumab in isolated polymyalgia rheumatica: a systematic literature review. Semin Arthritis Rheum 50:521–525

    CAS  PubMed  Google Scholar 

  17. Akiyama M, Kaneko Y, Takeuchi T (2020) Effectiveness of tocilizumab in Behcet's disease: a systematic literature review. Semin Arthritis Rheum 50:797–804

    CAS  PubMed  Google Scholar 

  18. van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC (2018) International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 132:2115–2124

    PubMed  PubMed Central  Google Scholar 

  19. Akiyama M, Yasuoka H, Takeuchi T (2017) Interleukin-6 in idiopathic multicentric Castleman’s disease after long-term tocilizumab. Ann Hematol 96:2117–2119

    CAS  PubMed  Google Scholar 

  20. Simeni Njonnou SR, Deuson J, Royer-Chardon C, Vandergheynst FA, Wilde V (2020) Unexplained cause of thrombocytopenia, fever, anasarca and hypothyroidism: TAFRO syndrome with thrombotic microangiopathy renal histology. BMJ Case Rep 13:e234155

    PubMed  Google Scholar 

  21. Kawabata H, Kotani S, Matsumura Y, Kondo T, Katsurada T, Haga H, Kadowaki N, Takaori-Kondo A (2013) Successful treatment of a patient with multicentric Castleman’s disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody. Intern Med 52:1503–1507

    PubMed  Google Scholar 

  22. Iwaki N, Sato Y, Takata K, Kondo E, Ohno K, Takeuchi M, Orita Y, Nakao S, Yoshino T (2013) Atypical hyaline vascular-type Castleman’s disease with thrombocytopenia, anasarca, fever, and systemic lymphadenopathy. J Clin Exp Hematop. 53:87–93

    PubMed  Google Scholar 

  23. Kubokawa I, Yachie A, Hayakawa A, Hirase S, Yamamoto N, Mori T, Yanai T, Takeshima Y, Kyo E, Kageyama G, Nagai H, Uehara K, Kojima M, Iijima K (2014) The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman’s disease. BMC Pediatr 14:139

    PubMed  PubMed Central  Google Scholar 

  24. Fujiwara S, Mochinaga H, Nakata H, Ohshima K, Matsumoto M, Uchiba M, Mikami Y, Hata H, Okuno Y, Mitsuya H, Nosaka K (2016) Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids. Int J Hematol 103:718–723

    CAS  PubMed  Google Scholar 

  25. Sakashita K, Murata K, Inagaki Y, Oota S, Takamori M (2016) An anterior mediastinal lesion in TAFRO syndrome showing complete remission after glucocorticoid and tocilizumab therapy. Respirol Case Rep 4:e00173

    PubMed  PubMed Central  Google Scholar 

  26. Simons M, Apor E, Butera JN, Treaba DO (2016) TAFRO syndrome associated with EBV and successful triple therapy treatment: case report and review of the literature. Case Rep Hematol 2016:4703608

    PubMed  PubMed Central  Google Scholar 

  27. José FF, Kerbauy LN, Perini GF, Blumenschein DI, Pasqualin DD, Malheiros DM et al (2017) A life-threatening case of TAFRO syndrome with dramatic response to tocilizumab, rituximab, and pulse steroids: the first case report in Latin America. Medicine (Baltimore) 96:e6271

    Google Scholar 

  28. Fujiki T, Hirasawa S, Watanabe S, Iwamoto S, Ando R (2017) Successful treatment by tocilizumab without steroid in a very severe case of TAFRO syndrome. CEN Case Rep 6:105–110

    PubMed  PubMed Central  Google Scholar 

  29. Kikuchi T, Shimizu T, Toyama T, Abe R, Okamoto S (2017) Successful treatment of TAFRO syndrome with tocilizumab, prednisone, and cyclophosphamide. Intern Med 56:2205–2211

    PubMed  PubMed Central  Google Scholar 

  30. Hou T, Dhillon J, Xiao W, Jaffe ES, Sands AM, Neppalli V, Deeb G, Zhang N (2017) TAFRO syndrome: a case report and review of the literature. Hum Pathol (N Y) 10:1–4

    Google Scholar 

  31. Sakai K, Maeda T, Kuriyama A, Shimada N, Notohara K, Ueda Y (2018) TAFRO syndrome successfully treated with tocilizumab: a case report and systematic review. Mod Rheumatol 28:564–569

    PubMed  Google Scholar 

  32. Takayama Y, Kubota T, Ogino Y, Ohnishi H, Togitani K, Yokoyama A (2018) TAFRO syndrome with disseminated intravascular coagulation successfully treated with tocilizumab and recombinant thrombomodulin. Intern Med 57:1291–1296

    PubMed  Google Scholar 

  33. Fujiwara Y, Ito K, Takamura A, Nagata K (2018) The first case of thrombocytopenia, anasarca, fever, renal impairment or reticulin fibrosis, and organomegaly (TAFRO) syndrome with unilateral adrenal necrosis: a case report. J Med Case Rep 12:295

    PubMed  PubMed Central  Google Scholar 

  34. Suzuki K, Matsumoto T, Iwashita Y, Ishikura K, Fujioka M, Wada H, Katayama N, Imai H (2019) Clinicopathological features of TAFRO syndrome complicated by acquired hemophilia a and development of cardiopulmonary arrest that were successfully treated with VA-ECMO and tocilizumab. Int J Hematol 109:737–743

    CAS  PubMed  Google Scholar 

  35. Nagayama Y, Yamano M, Yagame M, Nariyama T, Takahashi M, Kawamoto M, Matsui K (2019) TAFRO syndrome as a cause of glomerular microangiopathy: a case report and literature review. BMC Nephrol 20:375

    PubMed  PubMed Central  Google Scholar 

  36. Louis C, Vijgen S, Samii K, Chalandon Y, Terriou L, Launay D et al (2017) TAFRO syndrome in Caucasians: a case report and review of the literature. Front Med (Lausanne) 4:149

    Google Scholar 

  37. Mizuno H, Sekine A, Oguro M, Oshima Y, Kawada M, Sumida K, Yamanouchi M, Hayami N, Suwabe T, Hiramatsu R, Hasegawa E, Hoshino J, Sawa N, Fujii T, Takaichi K, Ohashi K, Ubara Y (2018) Renal histology in a patient with TAFRO syndrome: a case report. Hum Pathol 82:258–263

    PubMed  Google Scholar 

  38. Nara M, Komatsuda A, Itoh F, Kaga H, Saitoh M, Togashi M, Kameoka Y, Wakui H, Takahashi N (2017) Two cases of thrombocytopenia, Anasarca, fever, reticulin fibrosis/renal failure, and organomegaly (TAFRO) syndrome with high serum procalcitonin levels, including the first case complicated with adrenal hemorrhaging. Intern Med 56:1247–1252

    PubMed  PubMed Central  Google Scholar 

  39. Konishi Y, Takahashi S, Nishi K, Sakamaki T, Mitani S, Kaneko H, Mizutani C, Ukyo N, Hirata H, Tsudo M (2015) Successful treatment of TAFRO syndrome, a variant of multicentric Castleman’s disease, with cyclosporine a: possible pathogenetic contribution of interleukin-2. Tohoku J Exp Med 236:289–295

    PubMed  Google Scholar 

  40. Yamaga Y, Tokuyama K, Kato T, Yamada R, Murayama M, Ikeda T, Yamakita N, Kunieda T (2016) Successful treatment with cyclosporin a in tocilizumab-resistant TAFRO syndrome. Intern Med 55:185–190

    CAS  PubMed  Google Scholar 

  41. Tedesco S, Postacchini L, Manfredi L, Goteri G, Luchetti MM, Festa A, Gabrielli A, Pomponio G (2015) Successful treatment of a Caucasian case of multifocal Castleman’s disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report. Exp Hematol Oncol 4:3

    PubMed  PubMed Central  Google Scholar 

  42. Tatekawa S, Umemura K, Fukuyama R, Kohno A, Taniwaki M, Kuroda J, Morishita Y (2015) Thalidomide for tocilizumab-resistant ascites with TAFRO syndrome. Clin Case Rep. 3:472–478

    PubMed  PubMed Central  Google Scholar 

  43. Awano N, Inomata M, Kondoh K, Satake K, Kamiya H, Moriya A, Ando T, Kumasaka T, Takemura T, Takeuchi K, Ikushima S (2012) Mixed-type multicentric Castleman’s disease developing during a 17-year follow-up of sarcoidosis. Intern Med 51:3061–3066

    PubMed  Google Scholar 

  44. Ducoux G, Guerber A, Durel CA, Asli B, Fadlallah J, Hot A (2020) Thrombocytopenia, anasarca, fever, reticulin fibrosis/renal failure, and organomegaly (TAFRO) syndrome with bilateral adrenal hemorrhage in two Caucasian patients. Am J Case Rep 21:e919536

    PubMed  PubMed Central  Google Scholar 

  45. Minamikawa S, Matsumura O, Sato S, Nakagishi Y, Tanaka R. A pediatric case of tocilizumab-resistant TAFRO syndrome treated successfully with rituximab. Pediatr Blood Cancer. 2020:e28489

  46. Aoki T, Wada M, Kawashima A, Hirakawa K, Nagata A, Kagawa K (2017) Tocilizumab-resistant TAFRO syndrome complicated by type II respiratory failure. Intern Med 56:3249–3254

    PubMed  PubMed Central  Google Scholar 

  47. Oka S, Ono K, Nohgawa S (2018) Successful treatment of refractory TAFRO syndrome with elevated vascular endothelial growth factor using thyroxine supplements. Clin Case Rep 6:644–650

    PubMed  PubMed Central  Google Scholar 

  48. Tadokoro A, Kanaji N, Hara T, Matsumoto K, Ishii T, Takagi T, Watanabe N, Kita N, Kawauchi M, Ueno M, Kadowaki N, Bandoh S (2016) An uncharted constellation: TAFRO syndrome. Am J Med 129:938–941

    PubMed  Google Scholar 

  49. Shirai T, Onishi A, Waki D, Saegusa J, Morinobu A (2018) Successful treatment with tacrolimus in TAFRO syndrome: two case reports and literature review. Medicine (Baltimore) 97:e11045

    Google Scholar 

  50. Matsuhisa T, Takahashi N, Nakaguro M, Sato M, Inoue E, Teshigawara S, Ozawa Y, Kondo T, Nakamura S, Sato J, Ban N (2019) Fatal case of TAFRO syndrome associated with over-immunosuppression: a case report and review of the literature. Nagoya J Med Sci 81:519–528

    PubMed  PubMed Central  Google Scholar 

  51. Masaki Y, Kawabata H, Takai K, Tsukamoto N, Fujimoto S, Ishigaki Y et al (2020) 2019 updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol 111:155–158

    PubMed  Google Scholar 

  52. Iwaki N, Fajgenbaum DC, Nabel CS, Gion Y, Kondo E, Kawano M, Masunari T, Yoshida I, Moro H, Nikkuni K, Takai K, Matsue K, Kurosawa M, Hagihara M, Saito A, Okamoto M, Yokota K, Hiraiwa S, Nakamura N, Nakao S, Yoshino T, Sato Y (2016) Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 91:220–226

    CAS  PubMed  Google Scholar 

  53. Ishibashi T, Kimura H, Uchida T, Kariyone S, Friese P, Burstein SA (1989) Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro. Proc Natl Acad Sci U S A 86:5953–5957

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Eddahri F, Denanglaire S, Bureau F, Spolski R, Leonard WJ, Leo O, Andris F (2009) Interleukin-6/STAT3 signaling regulates the ability of naive T cells to acquire B-cell help capacities. Blood. 113:2426–2433

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, Rhee F et al (2016) Idiopathic multicentric Castleman’s disease: a systematic literature review. Lancet Haematol 3:163–175

    Google Scholar 

  56. Iwaki N, Gion Y, Kondo E, Kawano M, Masunari T, Moro H, Nikkuni K, Takai K, Hagihara M, Hashimoto Y, Yokota K, Okamoto M, Nakao S, Yoshino T, Sato Y (2017) Elevated serum interferon γ-induced protein 10 kDa is associated with TAFRO syndrome. Sci Rep 7:42316

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Pierson SK, Stonestrom AJ, Shilling D, Ruth J, Nabel CS, Singh A, Ren Y, Stone K, Li H, van Rhee F, Fajgenbaum DC (2018) Plasma proteomics identifies a ‘chemokine storm’ in idiopathic multicentric Castleman disease. Am J Hematol 93:902–912

    CAS  PubMed  Google Scholar 

  58. Antonelli A, Ferrari SM, Giuggioli D, Ferrannini E, Ferri C, Fallahi P (2014) Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev 13:272–280

    CAS  PubMed  Google Scholar 

  59. Galve-de Rochemonteix B, Nicod LP, Dayer JM (1996) Tumor necrosis factor soluble receptor 75: the principal receptor form released by human alveolar macrophages and monocytes in the presence of interferon gamma. Am J Respir Cell Mol Biol 14:279–287

    CAS  PubMed  Google Scholar 

  60. Widner B, Wirleitner B, Baier-Bitterlich G, Weiss G, Fuchs D (2000) Cellular immune activation, neopterin production, tryptophan degradation and the development of immunodeficiency. Arch Immunol Ther Exp 48:251–258

    CAS  Google Scholar 

  61. Morita K, Fujiwara SI, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Ochi SI, Nagayama T, Mashima K, Umino K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Yamamoto C, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Ashizawa K, Yamamoto Y, Oshiro H, Kanda Y (2019) TAFRO syndrome with an anterior mediastinal mass and lethal autoantibody-mediated thrombocytopenia: an autopsy case report. Acta Haematol 141:158–163

    CAS  PubMed  Google Scholar 

  62. Juskewitch JE, Norgan AP, De Goey SR, Duellman PM, Wakefield LL, Gandhi MJ et al (2017) How do I … manage the platelet transfusion-refractory patient? Transfusion. 57:2828–2835

    CAS  PubMed  Google Scholar 

  63. Leurs A, Gnemmi V, Lionet A, Renaud L, Gibier JB, Copin MC et al (2019) Renal pathologic findings in TAFRO syndrome: is there a continuum between thrombotic microangiopathy and membranoproliferative glomerulonephritis? A Case Report and Literature Review Front Immunol 10:1489

    PubMed  Google Scholar 

  64. Campbell L, Chen C, Bhagat SS, Parker RA, Östör AJ (2011) Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford) 50:552–562

    CAS  Google Scholar 

  65. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Takei S, Tanaka Y, Sano Y, Yaguramaki H, Yamanaka H (2014) Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol 41:15–23

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan

    Mitsuhiro Akiyama, Yuko Kaneko & Tsutomu Takeuchi

Authors
  1. Mitsuhiro Akiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuko Kaneko
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tsutomu Takeuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuko Kaneko.

Ethics declarations

Conflict of interest

M.A. reports no conflicts of interest relevant to this article. Y.K. has received grants or speaker fees from AbbVie, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Hisamitsu, Jansen, Kissei, Pfizer, Sanofi, Takeda, Tanabe-Mitsubishi, and UCB. T.T. has received research grants or speaking fees from Astellas Pharma Inc., Bristol–Myers K.K., Chugai Pharmaceutical Co, Ltd., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Teijin Pharma Ltd., AbbVie GK, Asahi Kasei Pharma Corp., Mitsubishi Tanabe Pharma, Astra Zeneca K.K., Eli Lilly Japan K.K., Novartis Pharma K.K., AbbVie GK, Nippon Kayaku Co. Ltd., Janssen Pharmaceutical K.K., Taiho Pharmaceutical Co., Ltd., and Pfizer Japan Inc.

Ethics approval

Local ethics committee approval was not required because this study was based on published data.

Patient consent for publication

Not required.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Akiyama, M., Kaneko, Y. & Takeuchi, T. Tocilizumab for the treatment of TAFRO syndrome: a systematic literature review. Ann Hematol 99, 2463–2475 (2020). https://doi.org/10.1007/s00277-020-04275-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-020-04275-0

Keywords

Search

Navigation